Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 71335-2494

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 71335-2494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 01)

Chemical structure of Desvenlafaxine Succinate, showing molecular components including aromatic rings, hydroxyl groups, amine groups, and succinate moiety with water of hydration.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 02)

A pharmacokinetic impact chart illustrating the effect of intrinsic factors such as renal impairment, hepatic impairment, and population characteristics (gender and age) on Desvenlafaxine exposure. It presents geometric mean ratios with 90% confidence intervals for Cmax and AUC, showing changes relative to reference values across varying impairment levels and demographic groups.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 03)

Pharmacokinetic graph showing the effect of the CYP3A4 inhibitor ketoconazole on desvenlafaxine. It plots the geometric mean ratio with 90% confidence intervals for Cmax and AUC, indicating an increase relative to reference values.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 04)

A figure titled 'Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs' presenting geometric mean ratios with 90% confidence intervals. The graph shows changes in pharmacokinetic parameters (Cmax, AUC) of drugs Desipramine, Midazolam, Tamoxifen, and Aripiprazole when co-administered with various doses of Desvenlafaxine (25 mg, 50 mg, 100 mg, 400 mg). The data is grouped by CYP2D6 substrate, CYP3A4 substrate, and CYP2D6 & CYP3A4 substrate categories.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 05)

A line graph titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)' showing the estimated proportion of patients with relapse (%) on the y-axis and time to relapse (days from randomization) on the x-axis. Two lines compare Desvenlafaxine extended-release tablets 50 mg and placebo over approximately 180 days, depicting a lower relapse proportion for Desvenlafaxine than placebo.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 06)

A Kaplan-Meier curve graph displaying the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine extended-release tablets and placebo groups. The graph shows relapse rates on the y-axis and time on the x-axis, with two lines representing each group over approximately 180 days.*

FDA Label Image

Label (Lbl713352494)

Desvenlafaxine Extended-Release Tablets 25 mg label with text indicating each film-coated ER tablet contains 38 mg Desvenlafaxine Succinate equivalent to 25 mg Desvenlafaxine. Label includes NDC 71335-2494-1, 30 tablets per package, repackaged by Bryant Ranch Prepack, and manufactured by Lupin Limited. Storage instructions and handling warnings are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.